TCGA-CF-A5UA-01A-11R-A28M-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.99080158
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.510
- FATTY_ACID_METABOLISM+0.270
- PANCREAS_BETA_CELLS+0.240
- MYC_TARGETS_V2+0.210
- DNA_REPAIR+0.190
- MYC_TARGETS_V1+0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.170
- PEROXISOME+0.160
- APICAL_SURFACE+0.150
- ESTROGEN_RESPONSE_LATE+0.150
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.430
- MITOTIC_SPINDLE-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- PROTEIN_SECRETION-0.400
- INTERFERON_GAMMA_RESPONSE-0.390
- TGF_BETA_SIGNALING-0.370
- IL6_JAK_STAT3_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.350
- INTERFERON_ALPHA_RESPONSE-0.340
- ALLOGRAFT_REJECTION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 85d43afd-9aac-48ca-a9c4-00357b7207e1 | — | — | 0.868 |
| 2 | 63e18642-fcf3-460b-95de-de16428dea6d | — | — | 0.856 |
| 3 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.855 |
| 4 | TCGA-CF-A47W-01A-11R-A23W-07 | — | — | 0.853 |
| 5 | cc1c7e4b-89a0-4d94-b9e5-293c2eacadd9 | — | — | 0.843 |
| 6 | TCGA-33-A5GW-01A-11R-A27Q-07 | — | cohortSQ2 | 0.842 |
| 7 | 0ffd0bed-35a4-4fec-9d56-1d4ae5dcb507 | — | — | 0.840 |
| 8 | TCGA-CF-A47T-01A-11R-A23W-07 | — | — | 0.840 |
| 9 | SRR9879286 | — | cohortSQ2 | 0.830 |
| 10 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |